We are dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs

Process and Manufacture

We have established a comprehensive quality management system in compliance with requirements applicable to and enforced by global competent authorities

Explore further

Company News

Bio-Thera Solutions Announces Commercialization and License A

GUANGZHOU, China, September 8, 2021 (BUSINESSWIRE) --Bio-Thera Solutions, Ltd. (688177.SH) today announced that it has entered into a commercialization and license agreement with Sandoz to commercializ...

Bio-Thera Solutions and Hikma Pharmaceuticals announce exclus

Guangzhou and London, 27 August 2021 – Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agree...

Bio-Thera Solutions Initiates Phase III Clinical Trial for BA

Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for BAT2506, a ...